Understand the source comparison
Best Peptides for IBS-C Constipation: Practical Comparison
Before selecting a peptide protocol, understanding how each candidate differs in mechanism, administration, and evidence level prevents mismatched expectations. BPC-157 Nitric oxide modulation, VEGF upregulation, mucosal repair Subcutaneous injection Preclinic
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understanding how each candidate differs in mechanism, administration, and evidence level prevents mismatched expectations.
- BPC-157
- Nitric oxide modulation, VEGF upregulation, mucosal repair
- Subcutaneous injection
- Preclinical (animal models, case reports)
- 7–14 days
- Improved colonic motility, faster transit time
- Best option for motility-dominant constipation
- KPV
- NF-κB inhibition, reduced mast cell degranulation
- Oral or subcutaneous
- Preclinical (IBD models, limited human data)
- 2–4 weeks
- Reduced visceral pain, improved mucosal barrier
- Best for inflammation-driven symptoms
- Thymosin Alpha-1
- T-regulatory cell modulation, systemic inflammation reduction
- Phase 2/3 trials (immunology), observational for IBS
- 4–8 weeks
- Reduced systemic inflammation, improved symptom scores
- Best for patients with concurrent autoimmune conditions
- Thymosin Beta-4
- Tissue repair, actin sequestration, anti-fibrotic effects
- Preclinical (wound healing models)
- 2–3 weeks
- Enhanced mucosal healing, reduced fibrosis
- Adjunct to other peptides for barrier restoration
- Patients often ask which peptide to start with. The answer depends on symptom profile. If the dominant issue is infrequent bowel movements with normal stool consistency when they occur. That's a motility problem. BPC-157 is the logical first choice. If the dominant issue is pain and bloating with hard, pellet-like stools. That's visceral hypersensitivity and inflammation. KPV becomes the priority. For patients with IBS-C secondary to autoimmune conditions (Hashimoto's, rheumatoid arthritis), thymosin alpha-1 addresses the systemic inflammation that compounds GI symptoms.